Skip to main content
. 2021 Mar 18;3(3):100276. doi: 10.1016/j.jhepr.2021.100276

Table 2.

Characteristics of cholestatic liver disease-diagnosed patients with serum samples.

All patients
n = 205
Early disease
n = 152
Advanced disease
n = 53
p value∗
Sex (F/M) 155/50 116/36 39/14 0.69
Aetiology (PBC/PSC) 147/58 108/44 39/14 0.72
Age (years) 51.4 ± 15.3 50.9 ± 15.6 53.0 ± 14.3 0.40
AMA+ (%) 55.5 56.4 52.9 0.67
ANA+ (%) 37.2 33.1 49.0 0.04
IgM (mg/dl) 238.8 ± 157.4 224.1 ± 159.2 281.4 ± 144.4 <0.01
AST (U/L) 52.2 ± 67.0 45.6 ± 71.4 70.4 ± 48.9 <0.01
ALP (U/L) 190.5 ± 161.4 171.6 ± 132.0 244.8 ± 218.1 <0.01
tBIL (mg/dl) 1.3 ± 2.1 1.0 ± 1.6 2.3 ± 2.8 <0.01
Albumin (g/dl) 4.2 ± 0.6 4.4 ± 0.4 3.7 ± 0.7 <0.01
Platelet (109/L) 210.8 ± 88.0 246.0 ± 58.8 109.7 ± 79.7 <0.01
LSM by VCTE (kPa) 8.5 ± 7.9 5.7 ± 1.6 20.8 ± 11.8 <0.01
APRI 0.9 ± 1.4 0.5 ± 0.8 2.2 ± 1.7 <0.01
Inadequate response to UDCA (%)# 50.2 39.5 81.1 <0.01
Anti-MCJ Ab (%) 17.1 15.8 20.8 0.41

#Biochemical response to UDCA was assessed using Paris-II criteria. Data are expressed as mean ± SD. ∗Early disease vs. advanced disease (Chi-square or Student t or Mann-Whitney U test). Bold values denote statistical significance. Ab, antibody; ALP, alkaline phosphatases; AMA, antimitochondrial antibodies; ANA, antinuclear antibodies; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; LSM, liver stiffness; tBIL, total bilirubin; UDCA, ursodeoxycholic acid; VCTE, vibration-controlled transient elastography.